io biotech regains nasdaq compliance after bid price recovery

IO Biotech (IOBT) has regained compliance with Nasdaq's minimum bid price requirement, as its stock maintained a closing bid price of $1.00 or higher for at least ten consecutive business days, according to a June 3, 2025, notification. This resolves a prior non-compliance issue stemming from a sub-$1.00 stock price for 30 consecutive days reported on December 26, 2024. The company, which specializes in pharmaceutical preparations, is now in good standing with Nasdaq listing rules.

Analysis

IO Biotech, Inc. (NASDAQ:IOBT) has successfully regained compliance with the Nasdaq Global Select Market’s minimum bid price requirement, as confirmed by Nasdaq’s Listing Qualifications Staff on June 3, 2025. This development indicates that IOBT's common stock maintained a closing bid price of $1.00 or higher for at least ten consecutive business days, thereby resolving a non-compliance issue first reported on December 26, 2024, which arose from its stock price falling below the $1.00 threshold for 30 consecutive trading days. For the Copenhagen-headquartered pharmaceutical preparations company, this news removes an immediate delisting risk and suggests a recent improvement in its stock performance. The article also references an AI-driven analysis by InvestingPro, highlighting that IOBT could be among potentially undervalued stocks, based on algorithms that reportedly identified other stocks in 2024 which subsequently experienced significant gains. While the overall sentiment score for this news is moderately positive (0.4) with a low market impact score (0.3), the sentiment specifically for IOBT is notably higher at 0.75, underscoring the direct positive implication for the company itself rather than a broader market shift.

Key Decisions for Investors

• Regaining Nasdaq compliance is a positive development for IOBT, substantially reducing the near-term delisting risk and likely improving investor perception of the stock's stability.
• Investors should consider the article's mention of AI-based analysis suggesting IOBT might be undervalued, prompting further independent investigation into the company's fundamental valuation and growth prospects.
• It is prudent to monitor IOBT's ability to consistently maintain its stock price above the $1.00 compliance level and look for tangible business catalysts beyond this technical achievement to support a sustained revaluation.